Article

B&L licenses 2 products for ophthalmic use

Rochester, NY-Bausch & Lomb has licensed two technologies for ophthalmic use. The company and Talecris Biotherapeutics, Research Triangle Park, NC, will co-develop rPlasmin, a recombinant derivative of the human blood component plasmin, which may have potential for use in developing novel therapies for ocular conditions. The agreement extends the partnership announced in 2005, in which Bausch & Lomb licensed plasma-delivered plasmin from Talecris predecessor Bayer Biological Products.

Rochester, NY-Bausch & Lomb has licensed two technologies for ophthalmic use. The company and Talecris Biotherapeutics, Research Triangle Park, NC, will co-develop rPlasmin, a recombinant derivative of the human blood component plasmin, which may have potential for use in developing novel therapies for ocular conditions. The agreement extends the partnership announced in 2005, in which Bausch & Lomb licensed plasma-delivered plasmin from Talecris predecessor Bayer Biological Products.

Bausch & Lomb is enrolling patients in early-stage clinical trials to evaluate plasmin's therapeutic potential to relieve retinal traction. Talecris is pursuing development of the technology for non-ocular applications, specifically to dissolve blood clots in veins and arteries.

Bausch & Lomb also has licensed a selective glucocorticoid receptor agonist from Schering AG of Berlin for the non-systemic treatment of eye disorders. The company will evaluate the compound's potential as a novel anti-inflammatory medication with an improved safety profile, due to its distinct molecular mechanism after binding to a glucocorticoid receptor, in ophthalmologic indications.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.